Comparison of 18 F-NOTA-NFB and 11 C-Methionine PET/MRI in Detecting Glioma Recurrence.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40644579.
- Also identified by DOI 10.1097/RLU.0000000000006059.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 37-year-old woman with recurrent glioblastoma in the right temporo-occipital lobe after surgery exhibited contrast-enhanced foci on contrast-enhanced MRI, with mild tracer uptake on 11 C-methionine PET/MRI and significantly increased tracer uptake on 18 F-NOTA-NFB, an 18 F-labeled chemokine receptor-4-targeted PET tracer, PET/MRI. 18 F-NOTA-NFB PET showed a significantly higher tumor-to-background ratio for recurrence than 11 C-methionine PET, allowing a more precise visualization of recurrent lesions. This case indicates that 18 F-NOTA-NFB PET/MRI might give advantages in glioma delineation that might provide valuable information for making a treatment strategy and personalized radiotherapy planning.
Medical subject headings
- Magnetic Resonance Imaging
- Methionine
- Positron-Emission Tomography
- Glioma
- Brain Neoplasms
- Heterocyclic Compounds
- Multimodal Imaging
- Neoplasm Recurrence, Local
- Heterocyclic Compounds, 1-Ring